Cationic liposome coupled endostatin gene for treatment of peritoneal colon cancer

Clinical and Experimental Metastasis

Volumn 27, Issue 5, 2010, Pages 307-318

  Lan, Keng Li ^a,b   Ou Yang, Fu ^c,d   Yen, Sang Hue ^a,b   Shih, How Ling ^a   Lan, Keng Hsin ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Angiogenesis; Bioluminescent imaging; Endostatin; Gene therapy; Liposome; Peritoneal carcinomatosis

Indexed keywords

BEVACIZUMAB; ENDOSTATIN; LIPOSOME; LUCIFERASE; CATION; PRIMER DNA; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; FEMALE; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; MOUSE; NONHUMAN; PERITONEAL COLON CANCER; PERITONEUM CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; APOPTOSIS; COLON TUMOR; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; METASTASIS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PERITONEUM TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BASE SEQUENCE; CATIONS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA PRIMERS; ENDOSTATINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE THERAPY; HUMANS; LIPOSOMES; MICE; PERITONEAL NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953944573     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-010-9328-x     Document Type: Article

References (48)

1. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 21 1182 1186 1:STN:280:DyaE38%2FgvVCqsQ%3D%3D 4938153
2. RS Kerbel 2008 Tumor angiogenesis N Engl J Med 358 19 2039 2049 10.1056/NEJMra0706596 1:CAS:528:DC%2BD1cXlsFyrtro%3D 18463380 (Pubitemid 351656458)
3. MS O'Reilly T Boehm Y Shing, et al. 1997 Endostatin: an endogenous inhibitor of angiogenesis and tumor growth Cell 88 2 277 285 10.1016/S0092-8674(00)81848-6 9008168 (Pubitemid 28015876)
4. A Abdollahi P Hahnfeldt C Maercker, et al. 2004 Endostatin's antiangiogenic signaling network Mol cell 13 5 649 663 10.1016/S1097-2765(04) 00102-9 1:CAS:528:DC%2BD2cXis1Kktbk%3D 15023336 (Pubitemid 38368123)
5. T Boehm J Folkman T Browder, et al. 1997 Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance Nature 390 6658 404 407 10.1038/37126 1:CAS:528:DyaK2sXns12rsL8%3D 9389480 (Pubitemid 28027321)
6. N Yamaguchi B Anand-Apte M Lee, et al. 1999 Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding EMBO J 18 16 4414 4423 10.1093/emboj/18.16.4414 1:CAS:528: DyaK1MXlslWgu7g%3D 10449407 (Pubitemid 29391251)
7. UK Zatterstrom U Felbor N Fukai, et al. 2000 Collagen XVIII/endostatin structure and functional role in angiogenesis Cell Struct Funct 25 2 97 101 10.1247/csf.25.97 1:CAS:528:DC%2BD3cXksVGit7g%3D 10885579 (Pubitemid 30453806)
8. J Folkman 2006 Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action Exp Cell Res 312 5 594 607 10.1016/j.yexcr.2005.11.015 1:CAS:528:DC%2BD28XhvVWltbY%3D 16376330 (Pubitemid 43290336)
9. RS Herbst KR Hess HT Tran, et al. 2002 Phase I study of recombinant human endostatin in patients with advanced solid tumors J Clin Oncol 20 18 3792 3803 10.1200/JCO.2002.11.061 1:CAS:528:DC%2BD38XntVyns70%3D 12228199
10. JP Eder Jr JG Supko JW Clark, et al. 2002 Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily J Clin Oncol 20 18 3772 3784 10.1200/JCO.2002.02.082 1:CAS:528:DC%2BD38XntVyns7w%3D 12228197
11. JP Thomas RZ Arzoomanian D Alberti, et al. 2003 Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors J Clin Oncol 21 2 223 231 10.1200/JCO.2003.12.120 1:CAS:528:DC%2BD2cXpsVWqsrc%3D 12525513 (Pubitemid 46606150)
12. MH Kulke EK Bergsland DP Ryan, et al. 2006 Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors J Clin Oncol 24 22 3555 3561 10.1200/JCO.2006.05.6762 1:CAS:528:DC%2BD28XovVSjs7o%3D 16877721 (Pubitemid 46630526)
13. L Persano M Crescenzi S Indraccolo 2007 Antiangiogenic gene therapy of cancer: current status and future prospects Mol Aspects Med 28 1 87 114 10.1016/j.mam.2006.12.005 1:CAS:528:DC%2BD2sXisVCnurs%3D 17306361 (Pubitemid 46320651)
14. CC Liu Z Shen HF Kung, et al. 2006 Cancer gene therapy targeting angiogenesis: an updated review World J Gastroenterol 12 43 6941 6948 1:CAS:528:DC%2BD28XhtlGhsr%2FK 17109514 (Pubitemid 44834883)
15. KL Lan SH Yen RS Liu HL Shih FW Tseng KH Lan 2007 Mutant Bik gene transferred by cationic liposome inhibits peritoneal disseminated murine colon cancer Clin Exp Metastasis 24 461 470 10.1007/s10585-007-9083-9 1:CAS:528:DC%2BD2sXhtlOiur%2FP 17636408 (Pubitemid 47367688)
16. YM Li Y Wen BP Zhou, et al. 2003 Enhancement of Bik antitumor effect by Bik mutants Cancer Res 63 22 7630 7633 1:CAS:528:DC%2BD3sXptFOls7c%3D 14633680 (Pubitemid 37466686)
17. N Weidner JP Semple WR Welch, et al. 1991 Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma N Engl J Med 324 1 1 8 1:STN:280:DyaK3M%2FnsVWquw%3D%3D 1701519 (Pubitemid 24058195)
18. H Hurwitz L Fehrenbacher W Novotny, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2335 2342 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D 15175435 (Pubitemid 38702844)
19. G Fuh P Wu WC Liang, et al. 2006 Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab J Biol Chem 281 10 6625 6631 10.1074/jbc.M507783200 1:CAS:528:DC%2BD28XhvFOgsLo%3D 16373345 (Pubitemid 43847597)
20. CH Contag D Jenkins PR Contag, et al. 2000 Use of reporter genes for optical measurements of neoplastic disease in vivo Neoplasia (New York, NY) 2 1-2 41 52 1:CAS:528:DC%2BD3cXlsVGhtb8%3D (Pubitemid 30123179)
21. A Abdollahi L Hlatky PE Huber 2005 Endostatin: the logic of antiangiogenic therapy Drug Resist Updat 8 1-2 59 74 10.1016/j.drup.2005.03.001 1:CAS:528:DC%2BD2MXltVaqtLg%3D 15939343 (Pubitemid 40797957)
22. A Whitworth 2006 Endostatin: are we waiting for Godot? J Natl Cancer Inst 98 11 731 733 16757695
23. H Jia J Kling 2006 China offers alternative gateway for experimental drugs Nat Biotechnol 24 2 117 118 10.1038/nbt0206-117 1:CAS:528: DC%2BD28XhtFGrtbg%3D 16465139 (Pubitemid 43221686)
24. G Bergers D Hanahan 2008 Modes of resistance to antiangiogenic therapy Nat Rev 8 8 592 603 1:CAS:528:DC%2BD1cXovV2lsrk%3D
25. RS Kerbel 2006 Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312 5777 1171 1175 10.1126/science.1125950 1:CAS:528:DC%2BD28XkvVOiur8%3D 16728631 (Pubitemid 43801134)
26. N Ferrara RS Kerbel 2005 Angiogenesis as a therapeutic target Nature 438 7070 967 974 10.1038/nature04483 1:CAS:528:DC%2BD2MXhtlSksrnI 16355214 (Pubitemid 43093963)
27. R Kerbel J Folkman 2002 Clinical translation of angiogenesis inhibitors Nat Rev 2 10 727 739 1:CAS:528:DC%2BD38XnsVGrtb0%3D (Pubitemid 37328908)
28. O Kisker CM Becker D Prox, et al. 2001 Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model Cancer Res 61 20 7669 7674 1:CAS:528:DC%2BD3MXnvFSht70%3D 11606410 (Pubitemid 32995064)
29. D Cross JK Burmester 2006 Gene therapy for cancer treatment: past, present and future Clin Med Res 4 3 218 227 10.3121/cmr.4.3.218 1:CAS:528:DC%2BD28XhtFeitb%2FE 16988102 (Pubitemid 44496015)
30. SD Li L Huang 2006 Gene therapy progress and prospects: non-viral gene therapy by systemic delivery Gene Ther 13 18 1313 1319 10.1038/sj.gt.3302838 1:CAS:528:DC%2BD28XptVClsLg%3D 16953249 (Pubitemid 44323687)
31. P Seth 2005 Vector-mediated cancer gene therapy: an overview Cancer Biol Ther 4 5 512 517 1:CAS:528:DC%2BD28Xitl2rtbo%3D 15908802 (Pubitemid 41351222)
32. ME Davis 2002 Non-viral gene delivery systems Curr Opin Biotechnol 13 2 128 131 10.1016/S0958-1669(02)00294-X 1:CAS:528:DC%2BD38Xis1Clt7k%3D 11950563 (Pubitemid 34310371)
33. K Kodama Y Katayama Y Shoji, et al. 2006 The features and shortcomings for gene delivery of current non-viral carriers Curr Med Chem 13 18 2155 2161 10.2174/092986706777935276 1:CAS:528:DC%2BD28XnslOksrc%3D 16918345 (Pubitemid 44137018)
34. T Niidome L Huang 2002 Gene therapy progress and prospects: nonviral vectors Gene Ther 9 24 1647 1652 10.1038/sj.gt.3301923 1:CAS:528: DC%2BD38XptFCisbo%3D 12457277 (Pubitemid 36104607)
35. A Dutour J Monteil F Paraf, et al. 2005 Endostatin cDNA/Cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: study in a human-like rat orthotopic tumor Mol Ther 11 2 311 319 10.1016/j.ymthe.2004.10.008 1:CAS:528:DC%2BD2MXms1Gksg%3D%3D 15668143
36. P Blezinger G Yin L Xie, et al. 1999 Intravenous delivery of an endostatin gene complexed in cationic lipid inhibits systemic angiogenesis and tumor growth in murine models Angiogenesis 3 3 205 210 10.1023/A:1009073028842 1:CAS:528:DC%2BD3cXmtVChtbo%3D 14517419 (Pubitemid 129644149)
37. Y Nakashima M Yano Y Kobayashi, et al. 2003 Endostatin gene therapy on murine lung metastases model utilizing cationic vector-mediated intravenous gene delivery Gene Ther 10 2 123 130 10.1038/sj.gt.3301856 1:CAS:528: DC%2BD3sXptF2isg%3D%3D 12571641 (Pubitemid 36582584)
38. D Simberg S Weisman Y Talmon, et al. 2003 The role of organ vascularization and lipoplex-serum initial contact in intravenous murine lipofection J Biol Chem 278 41 39858 39865 10.1074/jbc.M302232200 1:CAS:528:DC%2BD3sXnvFamsr8%3D 12869564 (Pubitemid 37248548)
39. NS Chiaramoni J Gasparri L Speroni MC Taira SD Alonso 2009 Biodistribution of liposome/DNA systems after subcutaneous and intraperitoneal inoculation J Liposome Res 10.3109/08982100903244518 19845441
40. S Kawakami Y Ito P Charoensit, et al. 2006 Evaluation of proinflammatory cytokine production induced by linear and branched polyethylenimine/plasmid DNA complexes in mice J Pharmacol Exp Ther 317 3 1382 1390 10.1124/jpet.105.100669 1:CAS:528:DC%2BD28Xlt1equ7w%3D 16522808 (Pubitemid 43764145)
41. JS Zhang F Liu L Huang 2005 Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity Adv Drug Deliv Rev 57 5 689 698 10.1016/j.addr.2004.12.004 1:CAS:528:DC%2BD2MXitFertb0%3D 15757755 (Pubitemid 40332597)
42. SW Dow LG Fradkin DH Liggitt, et al. 1999 Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously J Immunol 163 3 1552 1561 1:CAS:528: DyaK1MXkslOgsLk%3D 10415059
43. Y Yokoyama G Sedgewick S Ramakrishnan 2007 Endostatin binding to ovarian cancer cells inhibits peritoneal attachment and dissemination Cancer Res 67 22 10813 10822 10.1158/0008-5472.CAN-07-0172 1:CAS:528:DC%2BD2sXhtlSls7fL 18006826 (Pubitemid 350145910)
44. J Gong D Wang L Sun, et al. 1997 Role of alpha 5 beta 1 integrin in determining malignant properties of colon carcinoma cells Cell Growth Differ 8 1 83 90 1:CAS:528:DyaK2sXltVWkuw%3D%3D 8993837
45. A Garg AW Tisdale E Haidari, et al. 2009 Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide Int J Pharm 366 1-2 201 210 10.1016/j.ijpharm.2008.09.016 1:CAS:528:DC%2BD1cXhsFCjurvF 18835580
46. DJ Hicklin LM Ellis 2005 Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 23 5 1011 1027 10.1200/JCO.2005.06.081 1:CAS:528:DC%2BD2MXit1Gnsro%3D 15585754 (Pubitemid 46202320)
47. N Ferrara 2004 Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 25 4 581 611 10.1210/er.2003-0027 1:CAS:528:DC%2BD2cXns1Ght74%3D 15294883 (Pubitemid 39099316)
48. N Ferrara KJ Hillan HP Gerber, et al. 2004 Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 5 391 400 10.1038/nrd1381 1:CAS:528:DC%2BD2cXktlCrt78%3D 15136787 (Pubitemid 38618122)